UNSPSC 51273804: Alcohol/menthol/thymol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.

UNSPSC 51273804 Alcohol/menthol/thymol is a Commodity code that state and local governments use to procure pharmaceutical and over-the-counter products, though recent activity under this code shows significant mismatch between the nominal scope and actual solicitations. Seminole County, Florida, Seminole County, a county health department, has solicited naloxone and safe drug deactivation systems; the Texas Health and Human Services Commission has issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has solicited generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities. The issuing bodies include state health agencies, county health departments, and cooperative purchasing organizations serving multiple jurisdictions. Work actually being procured spans opioid-reversal medications, pharmaceutical manufacturing and supply chain capability, and bulk generic medication and OTC product distribution through authorized wholesaler networks—a scope broader than the code's name suggests and spanning both specialized emergency-response supplies and routine healthcare provisioning.

Activity appears concentrated in Florida and Minnesota, with multi-state reach through cooperative vehicles such as MMCAP. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be supplied through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026. The MMCAP solicitation indicates emphasis on pricing competitiveness (75 percent evaluation weight), cGMP and Drug Supply Chain Security Act compliance, and multi-wholesaler relationship capability. No explicit set-aside or disadvantaged-enterprise restrictions appear in the available documentation across the three opportunities.